GLP1R and obesity due to melanocortin 4 receptor deficiency: ,17 Since GLP-1 receptor agonists have only recently been used in obesity, we limited our analysis to patients with at least two coded diagnoses of type 2 diabetes between 2019 and 2024 (3,665,997 individuals).